INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09753537	
	Filing Date		2001-01-02	
	First Named Inventor David		vid L. Multer	
	Art Unit		2165	
	Examiner Name Abel		bel Jalii, Neveen	
	Attorney Docket Numb	er	FUSI-04105	

U.S.PATENTS

Remove

Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
1	7328341	B1	2008-02-05	Eun et al.			
2	7539697	B1	2009-05-26	Akella et al.			
3	7587398	B1	2009-09-08	Fredricksen et al.			
4	7707150	B2	2010-04-27	Sundararajan et al.			
h to add	additional U.S. Paten	t citatio	n information pl	ease click the Add button.	Add		
U.S.PATENT APPLICATION PUBLICATIONS Remove							
Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
1	20050144251	A1	2005-06-30	State			
2	20060233335	A1	2006-10-19	Pfleging et al.			
	1 2 3 4 4 Cite No.	No Patient Number 1 7328341 2 7539697 3 7587396 4 7707150 To add additional U.S. Paten Cite No Publication Number 1 20050144251	No Patient Number Code* 1 7328341 B1 2 7539697 B1 3 7587398 B1 4 7707150 B2 1to add additional U.S. Patient citation U.S.P Cite No Publication Kind Code* 1 20050144251 A1	No	No		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09753537
Filing Date		2001-01-02
First Named Inventor David		L. Multer
Art Unit		2165
Examiner Name Abel		Jalii, Neveen
Attorney Docket Number		FUSI-04105

	3	2	20070047533	A1	2007-03	I-01	Criddle et al.					
	4	1	20080064378	A1	2008-03	l-13	Kahan et al.					
	5	1	20090327305	A1	2009-12	1-31	Roberts et al.					
If you wis	h to a	dd ad	ditional U.S. Publis	shed Ap	plication	citatio	n information p	leas	e click the Add	butto	on. Add	
					FOREIG	SN PAT	TENT DOCUM	ENT	s		Remove	
Examiner Initial*	Cite No		ign Document iber ³	Country Code ²		Kind Code4		App	me of Patentee olicant of cited cument	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
	1											
If you wis	h to a	dd ad	ditional Foreign Pa	atent Do	cument	citation	information pl	ease	dick the Add	butto	n Add	
				NON	I-PATE	NT LITE	RATURE DO	CUM	IENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher. driven and/or country where publisher.					Ţs					
	1		divisory Action dated September 26, 2011, U.S. Patient Application Senal No. 12/037,609, Filed February 26, 2008, avid L. Multer, Attorney Docket No. FUSI-04110.									
If you wis	h to a	dd ad	ditional non-paten	t literatu	re docu	ment cit	ation informati	on p	lease click the	Add	button Add	_
					EX	AMINE	R SIGNATUR	E				_
Examiner	Sign	atura							Date Conside	rod		_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number		09753537	
Filing Date		2001-01-02	
First Named Inventor	David	L. Multer	
Art Unit		2165	
Examiner Name Abel		Jalil, Neveen	
Attorney Docket Numb	er	FUSI-04105	
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor David Art Unit	

See Risk Codes of USPTO Planto Documents at view USPTO, DOLL or MEPE P01.04. * Enter office and issued the occument, by the two letter code WIPO Standard ST3.3. ** For Legarance parted covaments, the includion of the paper of the region of the Engeror must provide the result invaries of the Engeror must provide the result invaries of the Engeror must provide the result invaries of the Standard ST3.0 ** Engelow the Engeror must provide the result invaries of the Standard ST3.0 ** Engelow the Standard ST3.0 ** En

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09753537
Filing Date		2001-01-02
First Named Inventor	David	L. Multer
Art Unit		2165
Examiner Name Abel		Jahl, Neveen
Attorney Docket Number		FUSI-04105

CERTIFICATION STATEMENT

Please see 37	CFR 1	.97 and	1.98 to make the	appropriate	selection(s)	
---------------	-------	---------	------------------	-------------	------------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involvidual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

David A Hill

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.			
Signature	/David A. Hill/	Date (YYYY-MM-DD)	2011-12-09

Registration Number

44 153

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Comments o

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested process and or examine your submission related to a patient application or patient. If you do not furnish the requested remaining the processing of the patient processing or the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.